What is the official website of Adelphi Access ?

The official website of Adelphi Access is http://www.adelphiaccess.com.

What is Adelphi Access's cybersecurity risk score?

Adelphi Access has an AI-generated cybersecurity risk score of 770 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Adelphi Access experienced?

According to Rankiteo, Adelphi Access currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Adelphi Access been affected by any supply chain cyber incidents ?

According to Rankiteo, Adelphi Access has been affected by a supply chain cyber incident involving Snowflake, with the incident ID ATT1764820523.

Does Adelphi Access have SOC 2 Type 1 certification ?

According to Rankiteo, Adelphi Access is not certified under SOC 2 Type 1.

Does Adelphi Access have SOC 2 Type 2 certification ?

According to Rankiteo, Adelphi Access does not hold a SOC 2 Type 2 certification.

Does Adelphi Access comply with GDPR ?

According to Rankiteo, Adelphi Access is not listed as GDPR compliant.

Does Adelphi Access have PCI DSS certification ?

According to Rankiteo, Adelphi Access does not currently maintain PCI DSS compliance.

Does Adelphi Access comply with HIPAA ?

According to Rankiteo, Adelphi Access is not compliant with HIPAA regulations.

Does Adelphi Access have ISO 27001 certification ?

According to Rankiteo,Adelphi Access is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Adelphi Access operate in ?

Adelphi Access operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Adelphi Access have ?

Adelphi Access employs approximately None employees people worldwide.

Does Adelphi Access own any subsidiaries ?

Adelphi Access presently has no subsidiaries across any sectors.

How many LinkedIn followers does Adelphi Access have ?

Adelphi Access's official LinkedIn profile has approximately followers.

What is the NAICS classification code for Adelphi Access ?

Adelphi Access is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Adelphi Access have a Crunchbase profile ?

No, Adelphi Access does not have a profile on Crunchbase.

Does Adelphi Access have a LinkedIn profile ?

Yes, Adelphi Access maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/adelphi-access.

How many cybersecurity incidents has Adelphi Access experienced ?

As of July 30, 2026, Rankiteo reports that Adelphi Access has experienced 1 cybersecurity incidents.

How many peer or competitor companies does Adelphi Access have ?

Adelphi Access has an estimated 5,718 peer or competitor companies worldwide.

What types of cybersecurity incidents has Adelphi Access faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Adelphi Access

Boost Score +25 with badge (5 left)

770

/1000

Fair

795

/1000

Fair

Adelphi Access Vendor Cyber Rating & Cyber Score

adelphiaccess.com

Add Your Compliance Badge

We’re an insight-led global consultancy dedicated to helping our clients develop winning commercial strategies for today’s and tomorrow’s healthcare markets. Why do we exist? Market success is getting the right medicines to the patients who need them at a commercially viable price; it relies on ensuring that all those involved in making the decisions are convinced that the benefits justify the investment. We exist to give our clients honest and practical advice about the collective decision making that will take place for their brand, to help them evaluate their options and, ultimately, position their brand for success. Who are we? We’re a team of consultants who want to work on interesting challenges and genuinely enjoy helping

Adelphi Access A.I CyberSecurity Scoring

Scoring History

Adelphi Access

Adelphi Access CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Omnicom

Breach

1/2024

Snowflake

ATT1764820523

Loading…

A.I.

Adelphi Access Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Adelphi Access

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Adelphi Access in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Adelphi Access in 2026.

Incident Types Adelphi Access vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Adelphi Access in 2026.

Incident History - Adelphi Access (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Adelphi Access Subsidiaries

Adelphi Access

Pharmaceutical Manufacturing

Website: http://www.adelphiaccess.com

Company Size: None employees

Omnicom HealthMarketing Services

Healthcare Consultancy Group - HCGAdvertising Services

OmnicomAdvertising Services

FlywheelAdvertising Services

Omnicom AdvertisingAdvertising Services

Omnicom Precision Marketing GroupAdvertising Services

Omnicom Specialty Marketing GroupAdvertising Services

ProEd RegulatoryPublic Health

HCG Engagement GroupAdvertising Services

Synergy Medical CommunicationsAdvertising Services

Health Science Communications New JerseyAdvertising Services

Hyphen Digital ( HCG / Omnicom )Advertising Services

Harrison/StarAdvertising Services

Archbow ConsultingPharmaceutical Manufacturing

Adelphi Real WorldBusiness Consulting and Services

PROPELLERAdvertising Services

BioPharm CommunicationsAdvertising Services

Expert Perspectives by Engage Health MediaPharmaceutical Manufacturing

DDB Health New YorkAdvertising Services

SSCG Media GroupAdvertising Services

BioluminaAdvertising Services

CDM BarcelonaAdvertising Services

cdmpAdvertising Services

Addressable HealthAdvertising Services

Wildtype HealthAdvertising Services

Adelphi GroupPharmaceutical Manufacturing

MCIMarket Research

TBWA\WORLDHEALTHAdvertising Services

DDB Remedy LondonAdvertising Services

DDB Health BarcelonaAdvertising Services

The Planning ShopAdvertising Services

Ology Medical EducationWellness and Fitness Services

Excerpta Medica BV - Adelphi GroupPharmaceutical Manufacturing

2TN (2 the Nth)Pharmaceutical Manufacturing

Science & PurposeAdvertising Services

Loading…

Adelphi Access Similar Companies

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Novartis

cb novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Loading…

NEWS

Adelphi Access CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

July 20, 2017 07:00 AM

Army opens collaborative cybersecurity research center

ADELPHI LABORATORY CENTER, Md. -- The U.S. Army Research Laboratory opened the Army Cyber-research Analytics Laboratory, or ACAL, on Monday.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-67595

SUMMARY

VaahCMS versions 2.0.0 through 2.3.4 contain a malicious obfuscated JavaScript payload embedded in the Blade template responsible for rendering security OTP emails, allowing remote attackers to execute unauthorized code in any browser that renders the affected email template with JavaScript enabled. The payload establishes a WebSocket connection to a hardcoded command-and-control endpoint, installs a password-field keylogger using MutationObserver to capture dynamically added inputs, scrapes WhatsApp Web DOM content, and accepts remote commands to redirect or overwrite the rendered page.

Published

Date2026-07-29

Updated

Date2026-07-29

RISK INFORMATION (Score: 8.1)

cvss3

Base Score: 8.1

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.2

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.2

REFERENCES

CVE-2026-15157

SUMMARY

undici does not validate the type property of a duck-typed blob-like request body before using it as the Content-Type header on the HTTP/1.1 dispatcher. In undici before 6.28.0, from 7.0.0 up to before 7.29.0, and from 8.0.0 up to before 8.9.0, an application that passes a hand-rolled blob-like body (via request, stream, pipeline, or dispatch) whose type is derived from untrusted input allows an attacker to inject CRLF sequences and append arbitrary HTTP headers, potentially smuggling a second request past the upstream. Native Blob objects are safe because their constructor strips CRLF from the type, and fetch is unaffected because it validates headers, but ecosystem libraries that build duck-typed blob shapes from user input can reach the vulnerable path. This is the same defect class as CVE-2022-35948 and CVE-2026-1527, on a header sink that the earlier fixes did not cover. The issue is fixed in undici 6.28.0, 7.29.0, and 8.9.0.

Published

Date2026-07-29

Updated

Date2026-07-29

RISK INFORMATION (Score: 4.2)

cvss3

Base Score: 4.2

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:R/S:U/C:L/I:L/A:N

Impact Score

2.5

Exploitability

1.6

REFERENCES

CVE-2026-14643

SUMMARY

undici's cache interceptor mishandles optional whitespace placed around the equals sign of a qualified no-cache or private Cache-Control directive. In undici from 7.0.0 up to before 7.29.0 and from 8.0.0 up to before 8.9.0, the parser either drops the directive or stores a field name with literal quote characters, so the cache decision fails to recognize the qualification and the response is stored. In shared-cache mode, this lets a response containing one user's authenticated data be served from cache to a later caller, including an unauthenticated one, when both requests resolve to the same cache key. It affects applications that enable the cache interceptor in shared mode, forward Authorization headers upstream, and receive cacheable responses with qualified directives padded with whitespace around the equals sign. This is the whitespace-around-equals variant that the fix for CVE-2026-9678 did not normalize, and it is fixed in undici 7.29.0 and 8.9.0.

Published

Date2026-07-29

Updated

Date2026-07-29

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2025-69949

SUMMARY

kishan0725 Hospital Management System 4.0 is vulnerable to SQL Injection in check_availability.php via the parameters emailid and email.

Published

Date2026-07-29

Updated

Date2026-07-29

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2025-69945

SUMMARY

kishan0725 Hospital Management System 4.0 is vulnerable to SQL Injection in /doctor/edit-patient.php?editid=1.

Published

Date2026-07-29

Updated

Date2026-07-29

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

https://github.com/um-dsp/TaintRadar/blob/main/sql_injection_cves/hospitalmanagementsystemproject/20250811-hospital-management-system-edit-patient.php-editid-sqli/20250811-hospital-management-system-edit-patient.php-editid-sqli.md

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…